Stephen V. Liu, MD, discusses the 5-year overall survival data with atezolizumab and chemotherapy in patients with extensive-stage small cell lung cancer.
Martin Wermke, MD, discusses why the novel T-cell engager BI 764532 may serve as a promising treatment option targeting DLL3 in small cell lung cancer and neuroendocrine carcinomas .
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.